Review
Elderly Adults and Skin Disorders: Common Problems for Nondermatologists
Abstract
Diseases of elderly adults are becoming increasingly important as life expectancy gradually rises worldwide. To promote healthy aging, it is important to understand the skin changes associated with aging. This review focuses on the special considerations for some of the more common dermatological disorders in elderly adults and examines presentation, contributing factors, and association with systemic diseases.This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
References
1. Werner CA. The older population: 2010. 2010 Census briefs. http://www.census.gov/prod/cen2010/briefs/c2010br-09.pdf. Published November 2011. Accessed May 6, 2012.
2. Gilchrest BA. Skin aging and photoaging: an overview. J Am Acad Dermatol 1989; 21: 610–613.
3. Tindall JP, Smith JG Jr. Skin lesions of the aged and their association with internal changes. JAMA 1963; 186: 1039–1042.
4. Waller JM, Maibach HI. Age and skin structure and function, a quantitative approach (I): blood flow, pH, thickness, and ultrasound echogenicity. Skin Res Technol 2005; 1: 221–235.
5. Kligman AM. Perspectives and problems in cutaneous gerontology. J Invest Dermatol 1979; 73: 39–46.
6. Branchet MC, Boisnic S, Frances C, et al. Skin thickness changes in normal aging skin. Gerontology 1990; 36: 28–35.
7. Elias PM, Ghadially R. The aged epidermal permeability barrier: basis for functional abnormalities. Clin Geriatr Med 2002; 18: 103–120.
8. Chang E, Yang J, Nagavarapu U, et al. Aging and survival of cutaneous microvasculature. J Invest Dermatol 2002; 118: 752–758.
9. Tsuchida Y. The effect of aging and arteriosclerosis on human skin blood flow. J Dermatol Sci1993; 5: 175–181.
10. Fisher GJ, Kang S, Varani J, et al. Mechanisms of photoaging and chronological skin aging. Arch Dermatol 2002; 138: 1462–1470.
11. Chung JH, Eun HC. Angiogenesis in skin aging and photoaging. J Dermatol 2007; 34: 593–600.
12. Reddy VP, Obrenovich ME, Atwood CS, et al. Involvement of Maillard reactions in Alzheimer disease. Neurotox Res 2002; 4: 191–209.
13. Walcher D, Marx N. Advanced glycation end products and C-peptide-modulators in diabetic vasculopathy and atherogenesis. Semin Immunopathol 2009; 31: 103–111.
14. Peppa M, Uribarri J, Vlassara H. Glucose, advanced glycation end products, and diabetes complications: what is new and what works. Clin Diabetes 2003; 21: 186–187.
15. Pageon H. Reaction of glycation and human skin: the effects on the skin and its components, reconstructed skin as a model. Pathologie-biologie 2010; 58: 226–231.
16. Shah MG, Maibach HI. Estrogen and skin. An overview. Am J Clin Dermatol 2001; 2: 143–150.
17. Nelson HD, Humphrey LL, Nygren P, et al. Postmenopausal hormone replacement therapy: scientific review. JAMA 2002; 288: 872–881.
18. Weisshaar E, Dalgard F. Epidemiology of itch: adding to the burden of skin morbidity. Acta Derm Venereol 2009; 89: 339–350.
19. Ward JR, Bernhard JD. Willan’s itch and other causes of pruritus in the elderly. Int J Dermatol 2005; 44: 267–273.
20. Roberts WE. Dermatologic problems of older women. Dermatol Clin 2006; 24: 271–280.
21. Reich A, Stander S, Szepietowski JC. Drug-induced pruritus: a review. Acta Derm Venereol 2009; 89: 236–244.
22. Reich A, Stander S, Szepietowski JC. Pruritus in the elderly. Clin Dermatol 2011; 29: 15–23.
23. Elmariah SB, Lerner EA. Topical therapies for pruritus. Semin Cutan Med Surg 2011; 30: 118–126.
24. Hercogova J. Topical anti-itch therapy. Dermatol Ther 2005; 18: 341–343.
25. Pierard GE, Quatresooz P. What do you mean by eczema craquele? Dermatology 2007; 215: 3–4.
26. Sparsa A, Boulinguez S, Liozon E, et al. Predictive clinical features of eczema craquele associated with internal malignancy. Dermatology 2007; 215: 28–35.
27. Norman RA. Xerosis and pruritus in the elderly: recognition and management. Dermatol Ther 2003; 16: 254–259.
28. Rogers J, Harding C, Mayo A. Stratum corneum lipids: the effect of ageing and the seasons. Arch Dermatol Res 1996; 288: 765–770.
29. Rawlings VA, Watkinson A, Rogers J, et al. Abnormalities in stratum corneum structure, lipid composition, and desmosome degradation in soap-induced winter xerosis. J Cosmet Sci 1994; 45: 203–220.
30. Noiles K, Vender R. Are all seborrheic keratoses benign? Review of the typical lesion and its variants. J Cutan Med Surg 2008; 12: 203–210.
31. Hafner C, Vogt T. Seborrheic keratosis. J Dtsch Dermatol Ges 2008; 6: 664–677.
32. Izikson L, Sober AJ, Mihm MC Jr, et al. Prevalence of melanoma clinically resembling seborrheic keratosis: analysis of 9204 cases. Arch Derm 2002; 138: 1562–1566.
33. Ramos-E-Silva M, Carvalho JC, Carneiro SC. Cutaneous paraneoplasia. Clin Derm 2011; 29: 541–547.
34. LCD for removal of benign skin lesions (L27362). Contractor information. http://www.medicarenhic.com/pa/policies/Removal%20of%20Benign%20Skin%20Lesions%20%28L27362%29.pdf. Accessed May 6, 2012.
35. Oxman MN. Herpes zoster pathogenesis and cell-mediated immunity and immunosenescence. J Am Osteopath Assoc 2009; 109 (6 suppl 2): S13–S17.
36. Schmader K. Herpes zoster and postherpetic neuralgia in older adults. Clin Geriatr Med 2007; 23: 615–632.
37. Farage MA, Miller KW, Berardesca E, et al. Clinical implications of aging skin: cutaneous disorders in the elderly. Am J Clin Dermatol 2009; 10: 73–86.
38. Christo PJ, Hobelmann G, Maine DN. Post-herpetic neuralgia in older adults: evidence-based approaches to clinical management. Drugs Aging 2007; 24: 1–19.
39. Tseng HF, Smith N, Harpaz R, et al. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA 2011; 305: 160–166.
40. Voelker R. FDA expands age range for shingles vaccine. JAMA 2011; 305: 1526.
41. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352: 2271–2284.
42. Brand CU, Hunziker T, Yawalkar N, et al. IL-1 beta protein in human skin lymph does not discriminate allergic from irritant contact dermatitis. Contact Dermatitis 1996; 35: 152–156.
43. Buckley DA, Rycroft RJ, White IR, et al. The frequency of fragrance allergy in patch-tested patients increases with their age. Br J Dermatol 2003; 149: 986–989.
44. Saap L, Fahim S, Arsenault E, et al. Contact sensitivity in patients with leg ulcerations: a North American study. Arch Dermatol 2004; 140: 1241–1246.
45. Balato A, Balato N, Di Costanzo L, et al. Contact sensitization in the elderly. Clin Dermatol2011; 29: 24–30.
46. Piaserico S, Larese F, Recchia GP, et al. Allergic contact sensitivity in elderly patients. Aging Clin Exp Res 2004; 16: 221–225.
47. Prakash AV, Davis MD. Contact dermatitis in older adults: a review of the literature. Am J Clin Dermatol 2010; 11: 373–381.
48. Kirtschig G, Middleton P, Bennett C, et al. Interventions for bullous pemphigoid. Cochrane Database Syst Rev 2010; 10: CD002292.
49. Charneux J, Lorin J, Vitry F, et al. Usefulness of BP230 and BP180-NC16a enzyme-linked immunosorbent assays in the initial diagnosis of bullous pemphigoid: a retrospective study of 138 patients. Arch Dermatol 2011; 147: 286–291.
50. Kwatra SG, Jorizzo JL. Bullous pemphigoid: a case series with emphasis on long-term remission off therapy. J Dermatolog Treat 2012 March 4 [epub ahead of print].
51. Iwashita K, Matsuyama T, Akasaka E, et al. The incidence of internal malignancies in autoimmune bullous diseases. Tokai J Exp Clin Med 2007; 32: 42–47.
52. Song HJ, Han SH, Hong WK, et al. Paraneoplastic bullous pemphigoid: clinical disease activity correlated with enzyme-linked immunosorbent assay index for the NC16A domain of BP180. J Dermatol 2009; 36: 66–68.
53. Walsh SR, Hogg D, Mydlarski PR. Bullous pemphigoid: from bench to bedside. Drugs 2005; 65: 905–926.
54. Parker SR, Dyson S, Brisman S, et al. Mortality of bullous pemphigoid: an evaluation of 223 patients and comparison with the mortality in the general population in the United States. J Am Acad Dermatol 2008; 59: 582–588.
55. Aschwanden M, Jeanneret C, Koller MT, et al. Effect of prolonged treatment with compression stockings to prevent post-thrombotic sequelae: a randomized controlled trial. J Vasc Surg 2008; 47: 1015–1021.
56. Karthikesalingam A, Young EL, Hinchliffe RJ, et al. A systematic review of percutaneous mechanical thrombectomy in the treatment of deep venous thrombosis. Eur J Vasc Endovasc Surg2011; 41: 554–565.
57. Kirsner RS, Pardes JB, Eaglstein WH, et al. The clinical spectrum of lipodermatosclerosis. J Am Acad Dermatol 1993; 28: 623–627.
58. Miteva M, Romanelli P, Kirsner RS. Lipodermatosclerosis. Dermatol Ther 2010; 23: 375–388.
59. O’Meara S, Cullum NA, Nelson EA. Compression for venous leg ulcers. Cochrane Database Syst Rev 2009; 1: CD000265.
60. Baldursson B, Sigurgeirsson B, Lindelof B. Venous leg ulcers and squamous cell carcinoma: a large-scale epidemiological study. Br J Dermatol 1995; 133: 571–574.
61. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation.Circulation 2006; 113: e463–e654.
62. Hafner J, Schaad I, Schneider E, et al. Leg ulcers in peripheral arterial disease (arterial leg ulcers): impaired wound healing above the threshold of chronic critical limb ischemia. J Am Acad Dermtol 2000; 43: 1001–1008.
63. Lewis KG, Weinstock MA. Trends in nonmelanoma skin cancer mortality rates in the United States, 1969 through 2000. J Invest Dermatol 2007; 127: 2323–2327.
64. Giblin AV, Thomas JM. Incidence, mortality and survival in cutaneous melanoma. J Plast Reconstr Aesthet Surg 2007; 60: 32–40.
65. Wei-Passanese EX, Han J, Lin W, et al. Geographical variation in residence and risk of multiple nonmelanoma skin cancers in US women and men. Photo Photobiol 2012; 88: 483–489.
66. Kwasniak LA, Garcia-Zuazaga J. Basal cell carcinoma: evidence-based medicine and review of treatment modalities. Int J Dermatol 2011; 50: 645–658.
67. Bath-Hextall FJ, Perkins W, Bong J, et al. Interventions for basal cell carcinoma of the skin.Cochrane Database Syst Rev 2007; 1: CD003412.
68. Lansbury L, Leonardi-Bee J, Perkins W, et al. Interventions for non-metastatic squamous cell carcinoma of the skin. Cochrane Database Syst Rev 2010; 4: CD007869.
69. Martin GM. Impact of interval and combination therapies on the management of actinic keratosis: review and clinical considerations. J Dermatol Treat 2011; 22: 288–297.
70. Davis N. Modern concepts of melanoma and its management. Ann Plast Surg 1978; 1: 628–629.
71. Dennis LK, Vanbeek MJ, Beane Freeman LE, et al. Sunburns and risk of cutaneous melanoma: does age matter? A comprehensive meta-analysis. Ann Epidemiol 2008; 18: 614–627.
